Login
Super Investors ADAR1 Capital Management, LLC
AC

ADAR1 Capital Management, LLC

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$2.19B
Positions
266
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (12 quarters reported)

$2.19B $280M
Q4 23 Q3 24 Q2 25 Q1 26 Q3 26

$280M in Q4 2023 → $2.19B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
AS Abivax Sa 9.3% Added 14% 2,050,822 $203M
SS State Str SPDR S&P 500 ETF T 6.2% Added 38% 177,624 $135M
Protagonist Therapeutics Inc 6.1% Trimmed 1.0% 951,403 $134M
Roivant Sciences Ltd 5.1% Trimmed 2.5% 3,079,526 $113M
Immunovant Inc 3.3% Trimmed 9.2% 2,115,502 $71.5M
Denali Therapeutics Inc 2.0% Added 101% 2,072,050 $42.8M
ES Ea Series Trust 1.8% Unchanged 337,125 $39.9M
Septerna Inc 1.7% Added 3.6% 974,396 $38.1M
Agios Pharmaceuticals Inc 1.7% Trimmed 12% 1,139,464 $37.9M
Aura Biosciences Inc 1.5% Added 4038% 5,385,879 $33.8M
Viking Therapeutics Inc 1.5% Added 80% 1,034,749 $33.7M
Cytokinetics Inc 1.4% Added 0.8% 461,407 $30.4M
Insmed Inc 1.2% Added 0.4% 229,531 $26.2M
Freenome Inc 1.2% New 1,645,800 $25.9M
CT Celldex Therapeutics Inc New 1.2% Added 29% 799,304 $25.9M
Anteris Technologies Global 1.1% Added 2.9% 3,237,321 $25.2M
Bridgebio Pharma Inc 1.1% Added 115% 379,261 $25M
PP Praxis Precision Medicines I 1.1% Added 14% 84,751 $24.7M
Fulcrum Therapeutics Inc 1.1% Added 325% 6,648,027 $24.6M
Vir Biotechnology Inc 1.1% Trimmed 12% 2,158,839 $24.1M
Dbv Technologies S A 1.1% Added 281% 2,010,831 $23.6M
Enanta Pharmaceuticals Inc 1.0% Added 29% 1,733,320 $22.8M
Editas Medicine Inc 1.0% Unchanged 8,889,000 $22.8M
Spyre Therapeutics Inc 1.0% Trimmed 16% 237,567 $21.2M
Enliven Therapeutics Inc 0.9% Added 14% 442,682 $20.3M
Nurix Therapeutics Inc 0.9% Added 160% 813,236 $19.3M
SS Sanofi Sa 0.9% Added 714% 464,600 $19.2M
Revolution Medicines Inc 0.8% Unchanged 87,509 $18M
Sarepta Therapeutics Inc 0.8% Added 30% 952,063 $17.3M
Maze Therapeutics Inc 0.8% Added 88% 637,353 $17.3M
Adlai Nortye Group Ltd 0.7% Trimmed 2.0% 997,356 $16M
Rallybio Corp 0.7% Unchanged 926,352 $15.9M
Nektar Therapeutics 0.7% Added 5.7% 258,182 $15.6M
Urogen Pharma Ltd 0.7% Added 47% 369,785 $15M
Taysha Gene Therapies Inc 0.7% Added 0.6% 3,059,567 $14.9M
Monopar Therapeutics Inc 0.6% Trimmed 18% 179,032 $14.3M
Janux Therapeutics Inc 0.6% Added 96% 823,876 $14.2M
Rhythm Pharmaceuticals Inc 0.6% Added 1.8% 138,658 $13.2M
Prothena Corp PLC 0.6% Trimmed 2.1% 1,522,103 $12.8M
Cogent Biosciences Inc 0.6% Added 3117% 392,422 $12.6M
Regeneron Pharmaceuticals 0.6% Trimmed 26% 16,446 $12.5M
SS SPDR Series Trust 0.6% Unchanged 135,585 $12.4M
Tenax Therapeutics Inc 0.6% Added 2859% 6,524,151 $12.3M
Monte Rosa Therapeutics Inc 0.5% Added 365% 1,007,752 $12M
Abcellera Biologics Inc 0.5% New 822,163 $12M
EL Establishment Labs Hldgs Inc 0.5% Unchanged 185,619 $11.9M
V Vogenx Inc 0.5% New 522,175 $11.9M
Inhibikase Therapeutics Inc 0.5% Trimmed 23% 5,708,755 $11.7M
Ovid Therapeutics Inc 0.5% Trimmed 39% 4,560,813 $11.4M
AP Avalyn Pharmaceuticals Inc 0.5% Added 172% 397,719 $11.3M
TP Teva Pharmaceutical Inds Ltd 0.5% New 276,348 $10.9M
Amylyx Pharmaceuticals Inc 0.5% Trimmed 26% 366,968 $10.7M
Helix Acquisition Corp Iii 0.5% Unchanged 1,000,000 $10.5M
Beam Therapeutics Inc 0.5% New 420,981 $10.3M
Vor Biopharma Inc 0.5% Trimmed 22% 531,349 $10.1M
Viking Therapeutics Inc 0.5% New 100,000 $9.95M
Edgewise Therapeutics Inc 0.4% Added 70% 243,199 $9.87M
Kazia Therapeutics Ltd 0.4% Added 1472% 967,740 $9.29M
Climb Bio Inc 0.4% Trimmed 3.6% 792,936 $9.09M
PP Praxis Precision Medicines I Call 0.4% New 30,000 $8.74M

Showing top 60 of 266 positions.

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
Zai Lab Ltd Exited −3,369,034 −$64M —
CP Crinetics Pharmaceuticals In Exited −1,222,080 −$45.7M —
SS State Str SPDR S&P 500 ETF T Added +48,537 +$37M 6.2%
Aura Biosciences Inc Added +5,255,727 +$33M 1.5%
Freenome Inc New +1,645,800 +$25.9M 1.2%
AS Abivax Sa Added +246,119 +$24.4M 9.3%
Denali Therapeutics Inc Added +1,042,970 +$21.6M 2.0%
IM Inspire Med Sys Inc Trimmed −304,588 −$21.1M 0.2%
Fulcrum Therapeutics Inc Added +5,082,998 +$18.8M 1.1%
IT Ishares Tr Exited −62,500 −$18.8M —

Showing the 10 largest of 241 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
AS Abivax Sa Added +410,684 +$54.7M 11.0%
Terns Pharmaceuticals Inc Exited −914,699 −$48.2M —
Agios Pharmaceuticals Inc Added +1,147,381 +$42.6M 2.2%
SS State Str SPDR S&P 500 ETF T Added +53,147 +$39.7M 4.4%
Zai Lab Ltd Added +1,943,667 +$36.9M 2.9%
Beam Therapeutics Inc Exited −1,446,375 −$34.5M —
Editas Medicine Inc New +8,889,000 +$28.8M 1.3%
PP Praxis Precision Medicines I Added +72,753 +$24.4M 1.1%
Denali Therapeutics Inc Trimmed −842,375 −$21.7M 1.2%
Insmed Inc Added +193,128 +$20.6M 1.1%

Showing the 10 largest of 289 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 18, 2026

Company Action Shares changed Value of change % of portfolio
Avidity Biosciences Inc Exited −546,534 −$39.4M —
Denali Therapeutics Inc Added +1,819,339 +$34.9M 2.1%
Beam Therapeutics Inc New +1,446,375 +$34.5M 2.0%
CP Crinetics Pharmaceuticals In Added +829,963 +$30.1M 2.4%
Vir Biotechnology Inc New +2,744,714 +$24.6M 1.4%
Dbv Technologies S A New +1,012,866 +$21.2M 1.2%
IM Inspire Med Sys Inc Added +390,197 +$20.1M 1.2%
Terns Pharmaceuticals Inc Added +373,084 +$19.7M 2.8%
Rapt Therapeutics Inc Exited −509,679 −$17.3M —
SR Scholar Rock Hldg Corp Added +337,684 +$16.6M 1.2%

Showing the 10 largest of 286 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 18, 2026

Company Action Shares changed Value of change % of portfolio
Keros Therapeutics Inc Trimmed −5,370,413 −$109M —
Avidity Biosciences Inc Added +492,878 +$35.6M 2.9%
89bio Inc Exited −2,113,153 −$31.1M —
SS SPDR S&P 500 ETF Tr Exited −45,500 −$30.3M —
Bioage Labs Inc Trimmed −1,744,513 −$23.1M 0.1%
Terns Pharmaceuticals Inc Added +531,615 +$21.5M 1.6%
CT Celldex Therapeutics Inc New Added +537,325 +$14.6M 1.3%
IS Inventiva Sa New +2,709,846 +$12.6M 0.9%
Arbutus Biopharma Corp Added +2,511,883 +$12.1M 1.9%
Fulcrum Therapeutics Inc Added +912,137 +$10.3M 1.0%

Showing the 10 largest of 257 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
Bridgebio Pharma Inc Trimmed −4,455,000 −$440M 0.4%
Bridgebio Pharma Inc Trimmed −1,980,000 −$278M 0.3%
AS Abivax Sa Trimmed −1,720,514 −$146M 10.8%
Immunovant Inc Added +1,706,687 +$27.5M 3.4%
SS SPDR S&P 500 ETF Tr Added +32,000 +$21.3M 3.4%
Roivant Sciences Ltd Added +1,406,704 +$21.3M 4.8%
Prothena Corp PLC Trimmed −1,905,911 −$18.6M 1.3%
89bio Inc Added +1,237,170 +$18.2M 2.9%
UN Uniqure Nv New +200,000 +$11.7M 1.1%
Cg Oncology Inc Trimmed −274,299 −$11M 0.9%

Showing the 10 largest of 236 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Keros Therapeutics Inc Added +3,902,803 +$52.1M 11.0%
SS SPDR S&P 500 ETF Tr New +40,500 +$25M 3.8%
Prothena Corp PLC New +3,375,009 +$20.5M 3.1%
Roivant Sciences Ltd Trimmed −1,542,607 −$17.4M 3.4%
SS SPDR S&P 500 ETF Tr New +22,684 +$14M 2.1%
Springworks Therapeutics Inc Trimmed −183,696 −$8.63M 0.2%
Rapt Therapeutics Inc Exited −5,970,768 −$7.28M —
Immunovant Inc Trimmed −433,800 −$6.94M 1.3%
Cytomx Therapeutics Inc Added +3,034,378 +$6.89M 1.1%
AS Abivax Sa Added +861,321 +$6.59M 3.6%

Showing the 10 largest of 206 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
Keros Therapeutics Inc Added +1,463,215 +$14.9M 2.8%
Bridgebio Pharma Inc Trimmed −339,222 −$11.7M 2.2%
Ascendis Pharma A/s Trimmed −70,000 −$10.9M —
Mineralys Therapeutics Inc Trimmed −578,116 −$9.18M 0.8%
Springworks Therapeutics Inc New +207,778 +$9.17M 1.7%
IT Ishares Tr New +103,337 +$8.55M 1.6%
Janux Therapeutics Inc New +264,900 +$7.15M 1.3%
EG Endeavor Group Hldgs Inc Exited −210,729 −$6.59M —
IT Intra-cellular Therapies Inc New +48,044 +$6.34M 1.2%
Rapt Therapeutics Inc Added +4,796,455 +$5.85M 1.4%

Showing the 10 largest of 224 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 13, 2025

Company Action Shares changed Value of change % of portfolio
Royalty Pharma PLC Trimmed −1,046,703 −$26.7M 0.3%
Cytokinetics Inc Trimmed −496,973 −$23.4M 3.9%
Bridgebio Pharma Inc Trimmed −769,613 −$21.1M 3.7%
Inhibikase Therapeutics Inc New +5,103,005 +$16.6M 3.3%
Zai Lab Ltd Added +513,383 +$13.4M 5.5%
Ascendis Pharma A/s Trimmed −90,000 −$12.4M 2.0%
SS SPDR Ser Tr Added +110,000 +$10.1M 2.4%
Immunovant Inc Trimmed −344,229 −$8.53M 3.9%
Kezar Life Sciences Inc Trimmed −1,190,869 −$8M 0.2%
AS Abivax Sa Added +991,781 +$7.26M 2.2%

Showing the 10 largest of 292 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support